IMCR
Immunocore Holdings plc
$28.96
+1.19%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (78%)
Inst. Holders50 funds
Inst. Value$686.1M
Inst. Activity5 buys / 7 sells
SEC Reports2
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. X0·CIK 0001671927·Prev Close $28.62
Recent Activity
May 31, 2026
Press
Immunocore presented updated Phase 1 data for brenetafusp in heavily pretreated advanced melanoma at ASCO 2026, showing
Impact 6/10
May 31, 2026
announcement
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
<p align="center"><b>Immunocore presents updated Phase 1 data of brenetafusp in patients with heavil
May 27, 2026
Insider
Herbst Roy Steven was granted 27,492 shares
Director
May 27, 2026
Insider
Bell John Irving was granted 27,492 shares
Director
May 27, 2026
Insider
Peterson Kristine was granted 27,492 shares
Director
Apr 19, 2026
Press
Immunocore announced five-year overall survival data from a Phase 3 trial showing KIMMTRAK doubled survival rates in met
Impact 8/10
Apr 8, 2026
SEC
David Berman, an affiliate of Immunocore Holdings plc, filed a Form 144 to notify intent to sell 25,000 ADRs, representi
144 — Impact 3/10
Feb 25, 2026
SEC
Immunocore reported strong financial results for Q4 and full year 2025, with KIMMTRAK net sales of $104.5 million and $4
8-K — Impact 7/10
Price Targets
$63.49
+119.2% upside
Strong Buy
Current $28.96
Low $34.00
Median $62.00
High $100.00
13 analysts
$34.00
$100.00
Analyst Ratings
7Strong Buy
11Buy
5Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 20, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 14, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 16, 2026 | Jefferies | DOWNGRADE | Buy → Hold |
| Feb 26, 2026 | Needham | MAINTAIN | Buy → Buy |
| Feb 4, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.02 ▲ +110.2% | $-0.18 — $0.32 | 112% YoY | 11 |
| Next Q | $-0.01 ▲ +93.9% | $-0.19 — $0.31 | 0% YoY | 11 |
| Current FY | $0.14 ▲ +114.6% | $-0.45 — $1.17 | 119% YoY | 13 |
| Next FY | $-0.67 ▲ +52.1% | $-3.69 — $2.23 | -700% YoY | 13 |
Latest Reports
BULLISH
Press
6/10
Immunocore presented updated Phase 1 data for brenetafusp in heavily pretreated advanced melanoma at ASCO 2026, showing
May 31, 2026
NEUTRAL
144
3/10
David Berman, an affiliate of Immunocore Holdings plc, filed a Form 144 to notify intent to sell 25,000 ADRs, representi
Apr 8, 2026
BULLISH
8-K
7/10
Immunocore reported strong financial results for Q4 and full year 2025, with KIMMTRAK net sales of $104.5 million and $4
Feb 25, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RTW INVESTMENTS, LP | $146.8M | — |
| FMR LLC | $145.6M | — |
| WELLINGTON MANAGEMENT GROUP LLP | $141.9M | TRIM |
| Point72 Asset Management, L.P. | $33.2M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $30.8M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 27, 2026 | Herbst Roy | A | $0.00 |
| May 27, 2026 | Bell John | A | $0.00 |
| May 27, 2026 | Peterson Kristine | A | $0.00 |
| May 27, 2026 | Ratcliffe Peter | A | $0.00 |
| May 27, 2026 | Pao William | A | $0.00 |
50 institutional holders with $686.1M total value (23,676,941 shares) as of 2026-Q1. Top holders: RTW, FMR, WELLINGTON. Net selling activity: 7 institutions trimmed/exited vs 5 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 4,869,798 | $146.8M | 21.4% | — |
| 2 | FMR LLC | 4,829,154 | $145.6M | 21.2% | — |
| 3 | WELLINGTON MANAGEMENT GROUP LLP | 4,706,168 | $141.9M | 20.7% | TRIM -31.3% |
| 4 | Point72 Asset Management, L.P. | 1,102,271 | $33.2M | 4.8% | DOUBLED +118.6% |
| 5 | TWO SIGMA INVESTMENTS, LP | 1,021,265 | $30.8M | 4.5% | ADD +62.8% |
| 6 | BAKER BROS. ADVISORS LP | 734,397 | $22.1M | 3.2% | TRIM -68.4% |
| 7 | BlackRock, Inc. | 656,309 | $19.8M | 2.9% | ADD +99.4% |
| 8 | Hudson Bay Capital Management LP | 633,174 | $19.1M | 2.8% | ADD +65.1% |
| 9 | JANUS HENDERSON GROUP PLC | 594,712 | $17.9M | 2.6% | ADD +30.9% |
| 10 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 407,373 | $12.3M | 1.8% | — |
| 11 | D. E. Shaw & Co., Inc. | 335,191 | $10.1M | 1.5% | — |
| 12 | MORGAN STANLEY | 323,606 | $9.8M | 1.4% | — |
| 13 | Woodline Partners LP | 316,762 | $9.6M | 1.4% | ADD +52.7% |
| 14 | CITADEL ADVISORS LLC | 230,399 | $6.9M | 1.0% | NEAR_EXIT -79.3% |
| 15 | BANK OF AMERICA CORP /DE/ | 206,866 | $6.2M | 0.9% | — |
| 16 | MARSHALL WACE, LLP | 180,340 | $5.4M | 0.8% | DOUBLED +194.9% |
| 17 | RENAISSANCE TECHNOLOGIES LLC | 164,000 | $4.9M | 0.7% | TRIM -35.7% |
| 18 | Legal & General Group Plc | 156,143 | $4.7M | 0.7% | — |
| 19 | TD ASSET MANAGEMENT INC | 135,828 | $4.1M | 0.6% | TRIM -53.6% |
| 20 | GOLDMAN SACHS GROUP INC | 119,497 | $3.6M | 0.5% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | DOUBLED | 504,151 | 1,102,271 | +118.6% | $33.2M | 2026-Q1 |
| BAKER BROS. ADVISORS LP | TRIM | 2,322,656 | 734,397 | -68.4% | $22.1M | 2026-Q1 |
| BlackRock, Inc. | ADD | 329,099 | 656,309 | +99.4% | $19.8M | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 383,558 | 633,174 | +65.1% | $19.1M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | ADD | 454,404 | 594,712 | +30.9% | $17.9M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 61,163 | 180,340 | +194.9% | $5.4M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | TRIM | 292,764 | 135,828 | -53.6% | $4.1M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | TRIM | 109,849 | 42,920 | -60.9% | $1.3M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 28,164 | 19,492 | -30.8% | $587.7K | 2026-Q1 |
| HRT FINANCIAL LP | TRIM | 32,596 | 22,861 | -29.9% | $689.00 | 2026-Q1 |
| CWM, LLC | NEAR_EXIT | 91 | 16 | -82.4% | $482.00 | 2026-Q1 |
| Rockefeller Capital Management L.P. | NEAR_EXIT | 1,359 | 8 | -99.4% | $241.00 | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | NEW | — | 454,404 | — | $15.7M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 220,696 | 359,293 | +62.8% | $12.5M | 2025-Q4 |
| BlackRock, Inc. | ADD | 245,205 | 329,099 | +34.2% | $11.4M | 2025-Q4 |
| Woodline Partners LP | ADD | 207,438 | 316,685 | +52.7% | $11.0M | 2025-Q4 |
| MARSHALL WACE, LLP | TRIM | 123,242 | 61,163 | -50.4% | $2.1M | 2025-Q4 |
| SEI INVESTMENTS CO | ADD | 34,985 | 50,337 | +43.9% | $1.7M | 2025-Q4 |
| ALPS ADVISORS INC | ADD | 24,339 | 41,487 | +70.5% | $1.4M | 2025-Q4 |
| DnB Asset Management AS | ADD | 8,116 | 13,066 | +61.0% | $453.5K | 2025-Q4 |
| RHUMBLINE ADVISERS | DOUBLED | 540 | 2,872 | +431.9% | $99.7K | 2025-Q4 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 1,548 | 2,120 | +37.0% | $73.6K | 2025-Q4 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 500 | 100 | -80.0% | $3.5K | 2025-Q4 |
| HRT FINANCIAL LP | DOUBLED | 8,796 | 32,596 | +270.6% | $1.1K | 2025-Q4 |
| Point72 Asset Management, L.P. | TRIM | 820,425 | 535,831 | -34.7% | $19.5M | 2025-Q3 |
6 unique insiders with 6 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 27, 2026 | Herbst Roy Steven | Director | AWARD | 27,492 | — | — |
| May 27, 2026 | Bell John Irving | Director | AWARD | 27,492 | — | — |
| May 27, 2026 | Peterson Kristine | Director | AWARD | 27,492 | — | — |
| May 27, 2026 | Ratcliffe Peter John | Director | AWARD | 27,492 | — | — |
| May 27, 2026 | Pao William | Director | AWARD | 27,492 | — | — |
| May 27, 2026 | Kaul Siddharth | Director | AWARD | 27,492 | — | — |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
BULLISH
6/10
Immunocore presented updated Phase 1 data for brenetafusp in heavily pretreated advanced melanoma at
May 31, 2026
BULLISH
8/10
Immunocore announced five-year overall survival data from a Phase 3 trial showing KIMMTRAK doubled s
Apr 19, 2026
NEUTRAL
5/10
Immunocore announced it will present five-year overall survival data from the KIMMTRAK Phase 3 trial
Mar 17, 2026
Current analyst consensus: Buy (78% buy). Based on 23 analysts: 7 strong buy, 11 buy, 5 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$63.49 mean target
+119.2% upside
Strong Buy (1.60)
$34.00 Low
$100.00 High
| Metric | Value |
|---|---|
| Current Price | $28.96 |
| Target Low | $34.00 |
| Target Mean | $63.49 |
| Target Median | $62.00 |
| Target High | $100.00 |
| # Analysts | 13 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.02 | $-0.18 | $0.32 | 111.8% | +110.2% | 2↑ 0↓ | $0.1B | 12.6% | 11 |
| Next Q 2026-09-30 |
$-0.01 | $-0.19 | $0.31 | 0.0% | +93.9% | 2↑ 0↓ | $0.1B | 9.6% | 11 |
| Current FY 2026-12-31 |
$0.14 | $-0.45 | $1.17 | 119.2% | +114.6% | 4↑ 5↓ | $0.4B | 11.9% | 13 |
| Next FY 2027-12-31 |
$-0.67 | $-3.69 | $2.23 | -700.1% | +52.1% | 4↑ 3↓ | $0.5B | 8.5% | 13 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.024 | |
| 7d ago | $0.024 | |
| 30d ago | $-0.232 | +0.255 |
| 60d ago | $-0.232 | +0.255 |
| 90d ago | $-0.220 | +0.244 |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 14, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 16, 2026 | Jefferies | DOWNGRADE | Buy | Hold |
| Feb 26, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 11 | 5 | 0 | 0 | 78% | |
| May 1, 2026 | 7 | 11 | 5 | 0 | 0 | 78% | |
| Apr 1, 2026 | 7 | 11 | 5 | 0 | 0 | 78% | |
| Mar 1, 2026 | 8 | 11 | 4 | 0 | 0 | 83% | |
| Feb 1, 2026 | 8 | 11 | 4 | 0 | 0 | 83% | |
| Jan 1, 2026 | 8 | 10 | 4 | 1 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 31, 2026
announcement
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
<p align="center"><b>Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma</b></p>
May 6, 2026
earnings
Immunocore reports first quarter financial results and provides a business update
<p align="center"><strong>Immunocore reports first quarter financial results and provides a business update</strong></p>
May 5, 2026
earnings_calendar
IMCR Q1 2026 Earnings Before Market Open — 2026-05-05
May 4, 2026
short_interest
FTD: IMCR — 93,336 shares ($2.6M) failed to deliver
Settlement: 20260504, Price: $28.16, FTD Value: $2,628,341.76, IMMUNOCORE HLDGS PLC ADS
Apr 29, 2026
short_interest
FTD: IMCR — 77,812 shares ($2.2M) failed to deliver
Settlement: 20260429, Price: $28.79, FTD Value: $2,240,207.48, IMMUNOCORE HLDGS PLC ADS
Apr 22, 2026
short_interest
FTD: IMCR — 65,063 shares ($1.9M) failed to deliver
Settlement: 20260422, Price: $29.52, FTD Value: $1,920,659.76, IMMUNOCORE HLDGS PLC ADS
Apr 19, 2026
announcement
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
<p align="center"><b><i>KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melano
Apr 7, 2026
short_interest
FTD: IMCR — 130,441 shares ($4.2M) failed to deliver
Settlement: 20260407, Price: $31.94, FTD Value: $4,166,285.54, IMMUNOCORE HLDGS PLC ADS
Apr 6, 2026
other
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
<p align="center">Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference</p>
Apr 6, 2026
short_interest
FTD: IMCR — 170,319 shares ($5.3M) failed to deliver
Settlement: 20260406, Price: $30.83, FTD Value: $5,250,934.77, IMMUNOCORE HLDGS PLC ADS
Apr 2, 2026
short_interest
FTD: IMCR — 91,016 shares ($2.8M) failed to deliver
Settlement: 20260402, Price: $30.31, FTD Value: $2,758,694.96, IMMUNOCORE HLDGS PLC ADS
Apr 1, 2026
short_interest
FTD: IMCR — 60,087 shares ($1.8M) failed to deliver
Settlement: 20260401, Price: $30.15, FTD Value: $1,811,623.05, IMMUNOCORE HLDGS PLC ADS
Mar 17, 2026
announcement
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
<p align="center"><b><i>Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting</i></b>
Mar 3, 2026
other
Immunocore to present at upcoming investor conferences
<p align="center">Immunocore to present at upcoming investor conferences</p>
Feb 24, 2026
earnings_calendar
IMCR Q4 2025 Earnings After Market Close — 2026-02-24